Eli Lilly and Company
CorpDigest
Eli Lilly and Company
Company History
Founded 1876 in Indianapolis, Indiana
Last reviewed: 2026-06-03 · By Swet Parvadiya
1876, Indianapolis: Colonel Eli Lilly, a Civil War veteran who had studied pharmacy before the war, opened a small laboratory with $1,400 in capital and a conviction that medicine needed to be made more reliably. The pharmaceutical industry at the time was largely unregulated, and product quality varied wildly. Lilly's founding premise was manufacturing consistency — an unglamorous differentiator that turned out to matter enormously.
The 1923 insulin achievement changed the company's trajectory permanently. Working from a license agreement with the University of Toronto, Lilly became the first manufacturer to produce commercial quantities of insulin in North America. The drug saved lives that had no other option. It also established Lilly's position in diabetes biology — a therapeutic area the company would occupy, continuously, for the next century.
Prozac arrived in 1987. The antidepressant became one of the most prescribed drugs in American history and generated revenues that sustained Lilly through the 1990s with a comfort that, in retrospect, created institutional complacency. When the Prozac patent expired in 2001, the revenue cliff was sharp and immediate. The company spent the following fifteen years rebuilding its pipeline, including a particularly painful stretch of Alzheimer's drug failures that consumed enormous resources without yielding approvals.
The 2019 acquisition of Loxo Oncology for approximately $8 billion accelerated the oncology pipeline. POINT Biopharma followed in 2023, Morphic Therapeutic in 2024. Each deal added targeted therapy capability in areas — precision oncology, radiopharmaceuticals, integrin biology — where Lilly's internal research had identified opportunity but needed external acceleration.
Colonel Eli Lilly (1838-1898) founded Eli Lilly and Company in Indianapolis, Indiana, in 1876 with an initial investment of $1,400 and three employees. His founding philosophy—that pharmaceutical products should be manufactured to consistent quality standards, clearly labeled, and scientifically validated—was radical in an era when patent medicines of dubious content were widely marketed. Lilly's insistence on hiring trained chemists, testing raw materials for quality before use, and maintaining production records set a standard that eventually became industry practice when federal regulation arrived in the early twentieth century. He led the company until his death in 1898, by which point it had grown from a three-person operation to a substantial manufacturer with a growing national and international reputation for quality. His son Josiah K. Lilly Sr. Succeeded him and continued building the organization on the scientific foundations his father had laid.
Colonel Eli Lilly founded Eli Lilly and Company in Indianapolis, Indiana, with $1,400 in capital and three employees, producing liquid medicines (elixirs and fluid extracts) with a commitment to quality and scientific formulation that distinguished the company from the patent medicine industry of the era.
Lilly entered into an agreement with Frederick Banting, Charles Best, and the University of Toronto to commercially manufacture insulin, becoming the first company to produce insulin on a commercial scale. The launch of insulin production transformed treatment for type 1 diabetes and established Lilly's identity as a manufacturer of complex biological medicines.
In collaboration with Genentech, Lilly launched Humulin—the world's first commercially available recombinant DNA-derived human insulin and the first approved recombinant human protein drug. This landmark achievement demonstrated Lilly's capability to manufacture biological medicines produced through genetic engineering and positioned the company at the forefront of the emerging biotechnology industry.
The FDA approved Prozac (fluoxetine), Lilly's selective serotonin reuptake inhibitor antidepressant, which went on to become a cultural phenomenon and one of the most prescribed drugs in pharmaceutical history. Prozac generated peak annual revenues exceeding $2.6 billion and introduced the concept of the pharmaceutical blockbuster to mainstream American culture.
Generic competition following Prozac's US patent expiration devastated revenues for Lilly's flagship product almost overnight, costing the company more than $2 billion in annual revenue within a year. The experience forced a fundamental strategic reckoning about pipeline dependency and the importance of biologics and patent-protected innovations as revenue diversification strategies.
David A. Ricks assumed the role of Chief Executive Officer, succeeding John Lechleiter. Under Ricks, Lilly sharpened its strategic focus on a smaller number of therapeutic areas with genuine scientific differentiation, accelerated pipeline discipline, and began the business development program that would eventually include the acquisition of Loxo Oncology and other transformative transactions.
Lilly acquired Loxo Oncology for approximately $8 billion, bringing in a precision oncology platform that included selpercatinib (a RET kinase inhibitor) and pirtobrutinib (a BTK inhibitor). This acquisition seeded Lilly's next-generation oncology pipeline and demonstrated the company's willingness to make large strategic bets on targeted cancer therapies.
The FDA approved tirzepatide under the brand name Mounjaro for the treatment of type 2 diabetes in May 2022. Mounjaro's dual GIP and GLP-1 receptor agonism mechanism produced superior glycemic control and weight loss compared to existing therapies, and the drug immediately attracted extraordinary commercial interest for its off-label weight loss potential.
In November 2023, the FDA approved tirzepatide under the brand name Zepbound for chronic weight management in adults with obesity or overweight with at least one weight-related comorbidity. Zepbound's approval opened the obesity indication formally and accelerated what had already become an extraordinary commercial trajectory for tirzepatide, which was generating $5 billion in quarterly revenues by the end of 2024.
The FDA granted full approval to donanemab under the brand name Kisunla for early symptomatic Alzheimer's disease in July 2024, completing a 25-plus year scientific journey for Lilly in Alzheimer's research. In the same fiscal year, the company achieved approximately $45.0 billion in total revenues, representing a 32 percent increase year-over-year and marking Lilly's arrival as one of the most valuable pharmaceutical enterprises in the world.
Lilly acquired Morphic Therapeutic for approximately $3.2 billion, bringing integrin inhibitor technology with significant potential in inflammatory bowel disease and other autoimmune conditions. The acquisition reflected Lilly's ongoing business development strategy of complementing internal pipeline productivity with targeted external acquisitions in high-value therapeutic areas.
Lilly acquired Loxo Oncology in January 2019 for approximately $8 billion to acquire a precision oncology platform built around the concept of targeting specific genomic alterations in cancer regardless of tumor type. Loxo had pioneered the development of highly selective kinase inhibitors designed to minimize off-target effects while achieving exceptional on-target potency against genomically defined cancer populations. The acquisition was intended to accelerate Lilly's transformation into a precision medicine oncology leader at a time when the company recognized that undifferentiated cytotoxic chemotherapy partnerships were not a sustainable competitive strategy in oncology.
Lilly acquired Morphic Therapeutic in August 2024 for approximately $3.2 billion to access the company's integrin inhibitor platform, which includes MORF-057, an oral small-molecule inhibitor of α4β7 integrin with potential in inflammatory bowel disease including Crohn's disease and ulcerative colitis. The inflammatory bowel disease market represents a high-value segment that Lilly had not previously addressed with differentiated proprietary assets, and Morphic's oral small-molecule approach offered a potential advantage over existing large-molecule biologics like vedolizumab that require infusion or injection. The acquisition reflected Lilly's strategy of using its strong balance sheet and cash generation to acquire late-stage development assets that can be accelerated through its global clinical and commercial infrastructure.
Lilly acquired POINT Biopharma Global Inc. In October 2023 for approximately $1.4 billion to acquire the company's radioligand therapy (RLT) platform and manufacturing infrastructure. Radioligand therapies, which combine tumor-targeting molecules with radioactive isotopes to deliver targeted radiation to cancer cells, represent a rapidly advancing area of oncology following the commercial success of Novartis's Lutathera and Pluvicto. The acquisition gave Lilly access to POINT's proprietary radiopharmaceutical manufacturing facilities—a specialized industrial capability that is scarce globally—as well as a pipeline of RLT candidates in clinical development for prostate cancer and other malignancies.
Lilly acquired Prevail Therapeutics in January 2021 for approximately $1.04 billion upfront plus contingent payments to access the company's gene therapy platform targeting neurological diseases, particularly Parkinson's disease and related alpha-synucleinopathies. Prevail's lead asset, PR001, is an AAV9-based gene therapy designed to deliver a functional copy of the GBA1 gene to neurons, targeting the subset of Parkinson's disease patients with GBA1 mutations who face faster disease progression. The acquisition represented Lilly's first significant investment in the gene therapy space and reflected the company's strategy of expanding its neuroscience portfolio beyond small molecules and antibodies.
Eli Lilly and Company was founded May 10, 1876 by Colonel Eli Lilly (1838-1898, US Civil War veteran serving as Colonel in 9th Indiana Cavalry then later 26th Colored Cavalry of the Union Army) in Indianapolis, Indiana as small pharmaceutical laboratory, with Colonel Lilly's strategic vision combining quality manufacturing standards versus 'patent medicine' industry common during 1870s plus continued scientific approach to pharmaceutical development. Strategic milestones include 1881 first commercially mass-produced gelatin-coated medicines supporting pharmaceutical manufacturing advancement, 1922 commercial insulin production through partnership with University of Toronto (Banting and Best discovery), 1947 distribution of streptomycin antibiotic, 1954 polio vaccine distribution support, 1986 Prozac (fluoxetine) launch revolutionizing depression treatment, 2006 Humalog insulin growth, 2014 Trulicity (dulaglutide) GLP-1 launch supporting diabetes treatment, 2017 Verzenio (abemaciclib) cancer treatment launch, 2022 Mounjaro (tirzepatide) launch supporting diabetes and weight management revolution, 2023 Zepbound weight loss launch, plus various other strategic developments. Revenue grew to $45 billion (2024).
Eli Lilly and Company's tirzepatide (sold as Mounjaro for diabetes since May 2022 launch, Zepbound for weight management since November 2023 launch) represents transformational pharmaceutical breakthrough supporting GLP-1 + GIP dual agonist mechanism generating exceptional weight loss results (20%+ body weight reduction supporting various clinical trial outcomes versus Novo Nordisk's GLP-1-only Wegovy 15% weight loss results). Strategic context includes Mounjaro/Zepbound generating substantial revenue ($16+ billion combined 2024 revenue supporting major commercial performance) with continued growth trajectory through 2025+ supporting various market expansion. Industry projections suggest GLP-1 + GIP plus various successor compounds could become largest pharmaceutical category in history with potential $150+ billion annual industry revenue by 2030. Eli Lilly market capitalization growth from approximately $200 billion (2022) to $700+ billion (2024) reflecting exceptional shareholder value creation supporting Lilly's emergence as world's most valuable pharmaceutical company surpassing Johnson & Johnson, Novo Nordisk, plus various other pharmaceutical competitors. Strategic implications continue affecting Lilly's positioning.
Eli Lilly and Company partnered with University of Toronto researchers Frederick Banting and Charles Best in 1922 to commercialize insulin (recently discovered diabetes treatment by Banting, Best, James Collip supporting historic medical breakthrough), supporting subsequent decades of diabetes treatment leadership across various insulin generation evolution. Strategic milestones include 1923 commercial Iletin insulin launch (world's first commercial insulin product), continued insulin development across various generations (semisynthetic insulins, human insulin via recombinant DNA technology in 1980s, insulin analogs in 1990s-2000s), Humalog (1996 rapid-acting insulin) and Humulin establishing major commercial positioning. Strategic legacy continues with diabetes treatment representing core Lilly strategic focus across 100+ years, with continued evolution through GLP-1 receptor agonist development (Trulicity 2014, Mounjaro 2022) representing continued diabetes treatment innovation. The 1922 insulin breakthrough represents foundational moment supporting Eli Lilly's continued pharmaceutical industry leadership through various scientific innovation generations affecting consolidated business performance across various periods.
Eli Lilly and Company has committed substantial $50+ billion in cumulative manufacturing capacity investment through 2030 supporting various GLP-1 and other product manufacturing scale-up addressing substantial demand exceeding supply across various markets. Major investments include Indiana manufacturing expansion ($16+ billion across multiple Indiana sites supporting various manufacturing capacity), North Carolina manufacturing facility ($1+ billion plant supporting injectable manufacturing), Ireland Limerick facility ($1+ billion investment supporting various API manufacturing), various other manufacturing investments across multiple countries supporting global manufacturing capacity. Strategic context includes continued GLP-1 supply shortages affecting various commercial dynamics (Wegovy and Zepbound supply constraints have affected various patient access through various periods), continued demand expansion across diabetes and obesity treatment categories, manufacturing capacity representing critical competitive advantage supporting various commercial dynamics, and various other strategic factors. Future manufacturing capacity completion supports continued commercial expansion supporting various market opportunities through ongoing GLP-1 industry evolution.